<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04136886</url>
  </required_header>
  <id_info>
    <org_study_id>B2019-070-01</org_study_id>
    <nct_id>NCT04136886</nct_id>
  </id_info>
  <brief_title>Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal Carcinoma</brief_title>
  <acronym>IMRT</acronym>
  <official_title>Intensity-modulated Radiotherapy Plus Concurrent Chemotherapy Versus Intensity-modulated Radiotherapy Alone In Patients With rT3/T4 Locally Advanced Recurrent Nasopharyngeal Carcinoma: A Phase 3 Multicenter Prospective Randomised Controlled Trial (IMRT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>JiangXi Province Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Province Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SiChuan Province Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hunan Province Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>YuNan Province Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GuiZhou Province Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hainan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated TongJi hospital of HuaZhong University of science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital of Nanchang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of FoShan City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether concurrent chemotherapy and IMRT is
      effective in the treatment of locally stage T3/T4 recurrent nasopharyngeal carcinoma patients
      compared with IMRT alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Locally T3/T4 recurrent nasopharyngeal carcinoma (NPC) may be salvaged by intensity
      modulated-radiotherapy (IMRT), but local control is not good enough and late toxicities is
      usually severe The aim of this phase III randomized controlled study is to address the
      efficacy of concurrent chemotherapy (cisplatin) with IMRT to improve local control and lower
      the occurrence of severe late toxicities compared with IMRT alone for locally T3/T4 recurrent
      NPC patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2027</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From the beginning the IMRT to 3 year after the end of IMRT</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with severe acute toxicities as assessed by CTCAE v3.0</measure>
    <time_frame>From the beginning of IMRT to 3 months after the end of IMRT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with grade 4-5 late adverse events as assessed by RTOG/EORTC Late Radiation Morbidity Scoring Schema</measure>
    <time_frame>From 3 months after the end of IMRT to 1 year after the end of IMRT</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">346</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>IMRT and concurrent cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IMRT and concurrent cisplatin to treat T3/T4 locally recurrent NPC patients. Cisplatin 100mg/M2 is to give D1,D22 of IMRT for 2 cycles. IMRT is to give GTV 60Gy in 27 fraction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMRT alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMRT alone to treat T3/T4 locally recurrent NPC patients. IMRT is to give 60Gy in 27 fraction</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>cisplatin is to give from the first Day of radiation therapy D1,D22 Q3W for 2 cycles Radiation: IMRT IMRT is to give 60Gy in 27 fraction</description>
    <arm_group_label>IMRT and concurrent cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT</intervention_name>
    <description>Radiation: IMRT IMRT is to give 60Gy in 27 fraction</description>
    <arm_group_label>IMRT alone</arm_group_label>
    <arm_group_label>IMRT and concurrent cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1.Pathologically or clinically confirmed rT3/T4 locally recurrent nasopharyngeal
             carcinoma;

             2.No evidence of distant metastasis

             3.More than 1 year from the end of the first course of radiotherapy

             4.Male, or female not in the phase of lactating or pregnancy

             5.ECOG 0-2

             6.Aged 18-70 years old

             7.WBC count ≥4×109/L, neutrophile granulocyte count≥1.5×109/L, PLT count ≥100×109/L,
             Hb ≥9g/L

             8.Total bilirubin, AST, ALT≤2.0 times of upper normal limits; creatinine ≤1.5 times of
             upper normal limits

             9.Written informed consort signed

        Exclusion Criteria:

          1. Only regionally recurrence

          2. Evidence of distant metastasis

          3. Prior invasive malignancy; noninvasive cancers (For example, carcinoma in situ of the
             bladder, oral cavity, or cervix are all permissible) are permitted

          4. Severe, active co-morbidity

          5. Prior anti-tumor treatment after diagnosis of local recurrence

          6. MRI was not performed 3 months after the first course of radiotherapy

          7. Abnormal function of heart, brain and lungs, etc

          8. Lactation or pregnancy

          9. Severe nasopharyngeal mucosal necrosis at the diagnosis of local recurrence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fei Han, doctor</last_name>
    <phone>8620-87343030</phone>
    <email>hanfei@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>hanyu wang, doctor</last_name>
    <phone>8620-87343418</phone>
    <email>wanghany@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>WangHanYu</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HanYu wang, PHD</last_name>
      <phone>008613925186898</phone>
      <email>why716@21cn.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Han F, Zhao C, Huang SM, Lu LX, Huang Y, Deng XW, Mai WY, Teh BS, Butler EB, Lu TX. Long-term outcomes and prognostic factors of re-irradiation for locally recurrent nasopharyngeal carcinoma using intensity-modulated radiotherapy. Clin Oncol (R Coll Radiol). 2012 Oct;24(8):569-76. doi: 10.1016/j.clon.2011.11.010. Epub 2011 Dec 29.</citation>
    <PMID>22209574</PMID>
  </reference>
  <reference>
    <citation>Xiao WW, Huang SM, Han F, Wu SX, Lu LX, Lin CG, Deng XW, Lu TX, Cui NJ, Zhao C. Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy: long-term results of a phase 2 study. Cancer. 2011 May 1;117(9):1874-83. doi: 10.1002/cncr.25754. Epub 2010 Nov 16.</citation>
    <PMID>21509764</PMID>
  </reference>
  <reference>
    <citation>Seo Y, Yoo H, Yoo S, Cho C, Yang K, Kim MS, Choi C, Shin Y, Lee D, Lee G. Robotic system-based fractionated stereotactic radiotherapy in locally recurrent nasopharyngeal carcinoma. Radiother Oncol. 2009 Dec;93(3):570-4. doi: 10.1016/j.radonc.2009.10.018. Epub 2009 Nov 16.</citation>
    <PMID>19919887</PMID>
  </reference>
  <results_reference>
    <citation>Guan Y, Liu S, Wang HY, Guo Y, Xiao WW, Chen CY, Zhao C, Lu TX, Han F. Long-term outcomes of a phase II randomized controlled trial comparing intensity-modulated radiotherapy with or without weekly cisplatin for the treatment of locally recurrent nasopharyngeal carcinoma. Chin J Cancer. 2016 Feb 15;35:20. doi: 10.1186/s40880-016-0081-7.</citation>
    <PMID>26879049</PMID>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 22, 2019</study_first_submitted>
  <study_first_submitted_qc>October 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2019</study_first_posted>
  <last_update_submitted>October 22, 2019</last_update_submitted>
  <last_update_submitted_qc>October 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Fei Han</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>concurrent chemotherapy</keyword>
  <keyword>IMRT</keyword>
  <keyword>recurrent NPC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

